'This is to inform you that
These facilities are used for the manufacture of drug substance of Pegfilgrastim and Recombinant Human Insulin and manufacturing related activities for Insulin Glargine and Insulin Aspart and were inspected by the regulatory agency
This certification will enable us to continue addressing the growing needs of patients in the EU markets and enhance access to our high quality biosimilars. We remain committed to global standards of quality and compliance.'
Contact:
Ms.
Tel: 080 2808 2808
Email: seema.ahuja@biocon.com
(C) 2020 Electronic News Publishing, source